Get the Stockscreener App
16.56
2.22%
0.36
Arrivent Biopharma Inc stock is traded at $16.56, with a volume of 225.37K.
It is up +2.22% in the last 24 hours and down -40.79% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
See More
Previous Close:
$16.20
Open:
$16.4
24h Volume:
225.37K
Relative Volume:
0.07
Market Cap:
$816.54M
Revenue:
Net Income/Loss:
$-166.31M
P/E Ratio:
-3.7128
EPS:
-4.4602
Net Cash Flow:
$-160.59M
1W Performance:
-0.90%
1M Performance:
-40.79%
6M Performance:
-43.69%
1Y Performance:
-19.53%
1-Day Range:
$15.97
$16.87
1-Week Range:
$15.26
$17.76
52-Week Range:
$11.36
$35.83
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
16.56 | 816.54M | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
509.86 | 129.23B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.75 | 94.92B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.00 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.32 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.60 | 42.04B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Dec-10-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
ArriVent BioPharma, Inc. (AVBP) stock price, news, quote and history - Yahoo Finance Singapore
Form 13D/A ArriVent BioPharma For: 8 October By Investing.com - Investing.com India
Form 13D/A ArriVent BioPharma For: 8 October By Investing.com - Investing.com Canada
BTIG cuts ArriVent BioPharma stock price target on trial results - Investing.com
Chinese biotech faces reality check as ArriVent drug failure sinks stock in US - South China Morning Post
Avbp stock hits 52-week low at 12.09 USD - Investing.com
ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP) - PR Newswire
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low - AOL.com
Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings - Benzinga
Why ArriVent BioPharma (AVBP) Stock Is Down Today - Quiver Quantitative
Why ArriVent BioPharma (AVBP) Stock Is Down Today - Quiver Quantitative
There are notable gap-ups and gap-downs in today's session. - ChartMill
ArriVent stock plunges on cancer trial failure (AVBP:NASDAQ) - Seeking Alpha
AVBP Stock Holds Range As Cash-Rich Biotech Plans Next Move - Timothy Sykes
AVBP Stock Holds Range As Cash-Rich Biotech Plans Next Move - Timothy Sykes
AVBP Slips 2.28% as ArriVent BioPharma Tests Support Near $26.86Runaway Gap - https://www.siam.in/
AVBP Slips 2.28% as ArriVent BioPharma Tests Support Near $26.86Volatility Breakout Picks - https://www.dars.gov.et/
(AVBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ArriVent’s ARR-002 Moves Forward in Early Ovarian and Endometrial Cancer Study - TipRanks
ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside Case (NASDAQ:AVBP) - Seeking Alpha
Are Medical Stocks Lagging AstraZeneca (AZN) This Year? - qz.com
Why Did ArriVent BioPharma (AVBP) Move Today? - Simply Wall Street
Why Did ArriVent BioPharma (AVBP) Move Today? - sahmcapital.com
ArriVent (AVBP) Trading: Posts a 2.95% Loss to $28.26 in the Current Update; Levels: Price Remains Between $26.85 Support and $29.67 ResistanceIV Spike - vinanet.vn
109,328 Shares in ArriVent BioPharma, Inc. $AVBP Acquired by E Fund Management Co. Ltd. - MarketBeat
We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth - Moomoo
HC Wainwright Issues Pessimistic Forecast for AVBP Earnings - MarketBeat
What is HC Wainwright's Estimate for AVBP FY2027 Earnings? - MarketBeat
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $47 - Moomoo
ArriVent BioPharma (AVBP) Could Be 56% Undervalued After The Allist China Licensing Deal - Sahm
H.C. Wainwright raises ArriVent BioPharma price target on trial outlook - Investing.com
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $47.00 - MarketBeat
H.C. Wainwright raises ArriVent BioPharma price target on trial outlook By Investing.com - Investing.com Canada
ArriVent Nears Pivotal Lung Cancer Data With $373 Million Cash - MyChesCo
ArriVent Biopharma price target lowered to $40 from $43 at Citi - TipRanks
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Technical Reactions to AVBP Trends in Macro Strategies - Stock Traders Daily
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $50 - Moomoo
ArriVent hands Allist Greater China rights to MUC16/NaPi2b ADC - AllSci
ArriVent BioPharma (NASDAQ:AVBP) Receives "Buy" Rating from Guggenheim - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% Following Weak Earnings - MarketBeat
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $42 to $50 - Moomoo
ArriVent BioPharma: Pipeline Progress and Funding Strength Support Buy Rating and Unchanged $42 Price Target - TipRanks
ArriVent BioPharma's (AVBP) "Buy" Rating Reaffirmed at BTIG Research - MarketBeat
Tema ETFs LLC Invests $1.98 Million in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Dimensional Fund Advisors LP Has $2.92 Million Stock Holdings in ArriVent BioPharma, Inc. $AVBP - MarketBeat
AVBP SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
ArriVent BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
ArriVent BioPharma (NASDAQ:AVBP) Posts Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
ArriVent inks China partnership for ARR-002 development - TipRanks
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):